ECSP034627A - Formulacion farmaceutica de gepirona para administracion oral - Google Patents

Formulacion farmaceutica de gepirona para administracion oral

Info

Publication number
ECSP034627A
ECSP034627A EC2003004627A ECSP034627A ECSP034627A EC SP034627 A ECSP034627 A EC SP034627A EC 2003004627 A EC2003004627 A EC 2003004627A EC SP034627 A ECSP034627 A EC SP034627A EC SP034627 A ECSP034627 A EC SP034627A
Authority
EC
Ecuador
Prior art keywords
amount
gepirone
pharmaceutical formulation
gepirona
oral administration
Prior art date
Application number
EC2003004627A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Gerardus Joseph Egberink
John F Engelhart
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ECSP034627A publication Critical patent/ECSP034627A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EC2003004627A 2000-12-08 2003-05-28 Formulacion farmaceutica de gepirona para administracion oral ECSP034627A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08

Publications (1)

Publication Number Publication Date
ECSP034627A true ECSP034627A (es) 2004-09-28

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004627A ECSP034627A (es) 2000-12-08 2003-05-28 Formulacion farmaceutica de gepirona para administracion oral

Country Status (19)

Country Link
EP (1) EP1343504A2 (cs)
JP (1) JP2004517083A (cs)
KR (1) KR20040018314A (cs)
CN (1) CN1479620A (cs)
AR (1) AR031461A1 (cs)
AU (1) AU2002226371A1 (cs)
BR (1) BR0115976A (cs)
CA (1) CA2436692A1 (cs)
CZ (1) CZ20031589A3 (cs)
EC (1) ECSP034627A (cs)
HU (1) HUP0401021A2 (cs)
IL (1) IL155855A0 (cs)
MX (1) MXPA03005099A (cs)
NO (1) NO20032581D0 (cs)
PL (1) PL362445A1 (cs)
RU (1) RU2003120446A (cs)
SK (1) SK6942003A3 (cs)
WO (1) WO2002045753A2 (cs)
ZA (1) ZA200303915B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
BRPI0419179A (pt) * 2004-11-05 2007-12-18 Fabre Kramer Pharmaceuticals I formulação de alta dosagem de liberação prolongada de gepirona
EP3657966A1 (en) * 2017-07-26 2020-06-03 Abbott Laboratories Nutritional tablets and methods of making the same
CN109745323A (zh) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 氮哌酮类化合物提高副交感神经活性的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
IL155855A0 (en) 2003-12-23
CZ20031589A3 (cs) 2003-11-12
BR0115976A (pt) 2003-12-30
PL362445A1 (en) 2004-11-02
WO2002045753A3 (en) 2002-08-29
SK6942003A3 (en) 2003-10-07
CN1479620A (zh) 2004-03-03
ZA200303915B (en) 2004-08-20
JP2004517083A (ja) 2004-06-10
NO20032581L (no) 2003-06-06
AR031461A1 (es) 2003-09-24
MXPA03005099A (es) 2004-02-12
WO2002045753A2 (en) 2002-06-13
AU2002226371A1 (en) 2002-06-18
HUP0401021A2 (hu) 2004-09-28
KR20040018314A (ko) 2004-03-03
RU2003120446A (ru) 2005-02-20
EP1343504A2 (en) 2003-09-17
NO20032581D0 (no) 2003-06-06
CA2436692A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
YU48600A (sh) Celekoksibne smese
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
KR970706815A (ko) 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
KR950703937A (ko) 안정한 서방성 경구 투여 조성물(Stable extended release oral dosage composition)
BR0312870A (pt) Comprimido de liberação sustentada compreendendo reboxetina
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
DK1348429T3 (da) Smelteekstruderede opioidformuleringer, der kan administreres oralt
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
BR0211198A (pt) Composições farmacêuticas e seu uso
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
WO2004098564A3 (en) Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
TWI313598B (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
BR0114100A (pt) Formulações de liberação controlada para administração oral
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses